NCT05005156 - Phase IIb Trial of Recombinant Novel Coronavirus Vaccine (Ad5-nCoV) in Adults 18 Years of Age and Older, Living With HIV | Biotech Hunter

Enrollment

155

Participants

Timeline

Start Date

June 24, 2021

Primary Completion Date

January 13, 2023

Study Completion Date

January 13, 2023

Conditions

Covid19

Interventions

BIOLOGICAL

Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV)

All participants will receive two doses vaccine and will be followed to monitor vaccine candidate safety, immunogenicity, and efficacy for a duration of 52 weeks. Fifty four days after the first vaccination, all participants will receive a second injection.

Trial Locations (4)

1002

Centro de Estudio Infectologicos (CEI), Capital Federal

1145

Helios Salud, Capital Federal

1425

Hospital Fernandez, Capital Federal

C1202ABB

Fundacion Huesped, CABA